Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors
NCT00029445 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2026-05-22
Summary
This study will collect white blood cells and plasma for research on how the immune system controls HIV infection. The immune system of a very small group of people with HIV, called non-progressors, has been able to control HIV for long periods without antiretroviral therapy. Some immune system-related genes important for this control have been identified in these patients.
People living with HIV who are 18 years of age and older, documented or suspected long-term nonprogressors in generally good health may be eligible to screen for the study.
Participants will undergo apheresis (a method for collecting larger quantities of certain blood components than can safely be collected through a simple blood draw) if venous access is adequate once yearly. Some may be asked to return every six months.
* Automated apheresis - Blood is drawn through a needle placed in an arm vein and spun in a machine, separating the blood components. The white cells are extracted and the red cells, with or without plasma (liquid part of the blood), are re-infused into the donor through a needle in the other arm. An anticoagulant (medication to prevent blood from clotting) is usually added to the blood while in the machine to prevent it from clotting during processing.
* Blood draw - a needle placed in an arm vein for large volume (approx 75ml) blood draw if veins considered inadequate for apheresis procedure.
Some of the blood collected through apheresis may be stored for future studies of HIV disease and immune function and for HLA testing, a genetic test of markers of the immune system.
...
Conditions
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Daniel C Rogan, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-08-09
Countries
- United States
Study Locations
More Related Trials
-
White Blood Cell Infusions to Treat HIV Infection
NCT00001647 ·Status: COMPLETED ·Phase: PHASE1
-
Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy
NCT01787994 ·Status: COMPLETED ·Phase: PHASE1
-
Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection
NCT00050284 ·Status: COMPLETED
-
Selection of a Protective T Cell-based HIV-1/FIV Vaccine
NCT02389595 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
NCT02463227 ·Status: COMPLETED ·Phase: PHASE1
-
A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3
NCT00001064 ·Status: TERMINATED ·Phase: NA
-
Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure
NCT03758625 ·Status: COMPLETED ·Phase: PHASE1
-
Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer
NCT00968630 ·Status: COMPLETED ·Phase: PHASE2
-
Analysis of Immune Responses to HIV Vaccines
NCT00068978 ·Status: COMPLETED
-
Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 Studies
NCT00311688 ·Status: COMPLETED
-
Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV
NCT00021762 ·Status: WITHDRAWN ·Phase: PHASE2
-
Safety and Survival of Genetically Modified White Blood Cells in HIV-Infected Persons - A Study in Identical Twin Pairs
NCT00001353 ·Status: COMPLETED
-
Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines
NCT00001210 ·Status: COMPLETED
-
Use of Labeled Glucose to Study Lymphocyte Replication and Survival in HIV-Infected Patients
NCT00001651 ·Status: TERMINATED ·Phase: NA
-
A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected Children
NCT00000827 ·Status: COMPLETED ·Phase: PHASE1
-
Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452
NCT00006495 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3
NCT00000756 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC
NCT00000680 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Prepare for Future HIV Vaccine Studies
NCT00029744 ·Status: COMPLETED
-
A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3
NCT00000779 ·Status: COMPLETED ·Phase: PHASE1
-
HIV Vaccine in HIV-uninfected Adults
NCT04658667 ·Status: COMPLETED ·Phase: PHASE1
-
Immune Responses to Two Experimental HIV Vaccines in Healthy Adults
NCT01386489 ·Status: COMPLETED ·Phase: PHASE1
-
Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV
NCT00011011 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Examination of B Cell Responses in Human Blood
NCT00806845 ·Status: COMPLETED
-
Evaluation of the Safety of and Immune Response to an HIV Vaccine in Healthy Adults
NCT00051454 ·Status: COMPLETED ·Phase: PHASE1/PHASE2